The GLP-1 Patent Cliff: What Happens in 2031 and 2032

If you are paying several hundred dollars a month for semaglutide and waiting for a cheap generic, the honest answer is that you are waiting until at least December 2031 in the United States, and probably longer for the exact product you use. This article explains why, what could change the date, and what the countries that already have generic semaglutide tell us about what happens next.

This is a market and policy explainer. It is not medical advice, and it is not a recommendation to delay or change treatment while waiting for a price to fall. Talk to a healthcare provider about your own care.

This page contains no dosing guidance. It does not describe what dose to take, how to change a dose, when to start or stop a medication, or how to combine one with another. Those are set by the FDA-approved prescribing information and Instructions for Use for each product, by your own prescription, and by your provider.

When does the semaglutide patent actually expire?

The main US compound patents covering semaglutide are US 8,129,343 (the ‘343 patent) and US 8,536,122 (the ‘122 patent) [1]. The two have diverged, and the difference is the whole story:

• US 8,536,122 ran its ordinary term and expired March 20, 2026 — twenty years from filing, with no extension [2].
• US 8,129,343 carries patent term adjustment and patent term extension and expires December 5, 2031 per the FDA Orange Book [1][2].

So the operative date is December 5, 2031, and the March 2026 date that occasionally surfaces online refers only to the unextended ‘122 patent. Semaglutide is not off patent in the United States.

Here is the part most people find surprising. A US patent normally lasts 20 years from the filing date. For semaglutide, 20 years from filing would have been March 2026 [1]. The December 2031 date exists because of two separate legal mechanisms that added more than five years:

• Patent term adjustment, which compensates a patent holder for delays at the US Patent and Trademark Office
• Patent term extension, which compensates for time lost to FDA review before a drug can be sold

The advocacy group I-MAK, which studies drug patents, estimates that those five extra years are worth a very large amount of revenue to Novo Nordisk [1]. That is not a moral argument in either direction, just the arithmetic of why 2031 rather than 2026.

Why do people say 2032 instead of 2031?

Because patent expiry and generic availability are not the same event.

I-MAK identified 320 US patent applications filed by Novo Nordisk related to its three semaglutide products [1]. More than 20 patents are listed in the FDA Orange Book for Ozempic alone, many of them covering the injection device rather than the molecule, with some running into the late 2030s [2].

The structural problem is captured in one statistic: across GLP-1 products, 54% of all listed patents cover delivery devices, not drugs [2]. A generic company can design around a device patent, but it takes time and money, and listing device patents in the Orange Book can trigger a 30-month stay on generic approval when a generic filer challenges them [2].

Oral semaglutide is protected further still. Patents on the solid oral formulation, such as US 11,833,248, run to February 2039, and other semaglutide method-of-use patents run to 2038 [3].

So the realistic answer is layered:

What	Realistic US timing
Compound patent expiry (‘343)	December 5, 2031 [1][2]
First generic injectable semaglutide, depending on litigation and device design	2031 to 2032 [1][4]
Meaningful price competition with multiple generics	after first entry, historically within 12 to 24 months
Generic oral semaglutide	later, on formulation patents running to 2038-2039 [3]

What the Mylan lawsuit tells us

There is already a public court fight that previews how this plays out.

Mylan Pharmaceuticals filed an abbreviated new drug application, or ANDA, seeking approval to sell a generic version of Wegovy. Novo Nordisk sued in the US District Court for the District of Delaware under the Hatch-Waxman Act, asserting five patents, including US 9,764,003 [4].

In July 2025, Judge Colm Connolly granted Mylan judgment on the pleadings under Rule 12(c) on one of those five patents, the ‘003 patent [5]. Note the scope: this was a district-court ruling at the pleading stage on a single patent, not a decision that Mylan may sell generic semaglutide. The other four asserted patents were unaffected, and the compound patent runs to December 2031 regardless. The reasoning matters. The ‘003 patent claims a method of reducing body weight by administering semaglutide “without another therapeutic agent.” Novo argued that Mylan’s proposed label discouraged combining semaglutide with other drugs, and that this implied intent to induce doctors to practice the patented method. The court disagreed, holding that inducement requires active encouragement, not mere foreseeability that physicians would prescribe the drug alone [5][6].

The lesson for consumers: the fight over generic semaglutide is likely to be fought sentence by sentence over what the generic label says, not over whether the molecule is copyable. Generic labels can be “carved out” to avoid patented uses, which sometimes means a generic launches for one indication before another.

Tirzepatide is a completely different clock

If you take Mounjaro or Zepbound, the timeline is much longer.

Tirzepatide’s key compound patent, US 9,474,780, was filed in 2015 and expires in the US on January 5, 2036 [1][2]. Pediatric exclusivity could push that into early 2037 [7]. Formulation patents such as US 11,357,820 run to June 2039 [8], and Lilly’s filings list US patents running from 2036 into the 2040s [7].

I-MAK counted 53 US patent applications and 16 granted patents on tirzepatide products as of its July 2024 landscaping [1]. The ‘780 patent is also broad: it covers not just tirzepatide but a set of other compounds targeting both the GLP-1 and GIP receptors, which discourages competitors from developing similar molecules [1].

Because peptides of this type typically follow a follow-on or biosimilar-style pathway rather than a simple generic pathway, analysts commonly project meaningful US tirzepatide price drops only around 2038 to 2040 [7].

This asymmetry is the single most important fact in the next decade of this market. For roughly five years, from about 2032 to 2036, the US will have cheap generic semaglutide and brand-only tirzepatide. That will change what doctors prescribe, what insurers prefer, and what people pay.

The rest of the world is already there

You do not have to speculate about what generic semaglutide looks like. Several large countries got it in 2026.

Semaglutide lost patent protection in India on March 20, 2026 [9], and in China, Brazil, Turkey and Canada during the same year [10]. IQVIA calculates that those markets together contain 38% of the world’s adults living with obesity [10].

What happened next in India:

• Multiple manufacturers launched almost immediately, including Dr. Reddy’s (brand OBEDA), Sun Pharma (Noveltreat), Glenmark (GLIPIQ), Alkem (Semasize, Obesema, Hepaglide) and Natco [9]
• Alkem launched on March 21, 2026 at roughly INR 450 per week, about INR 1,800 per month [9]
• Reported entry prices for vial-based generics fell as low as about INR 1,290 per month [11]
• Before expiry, branded Ozempic and Wegovy in India ran roughly INR 8,800 to 16,400 per month [11]
• Novo Nordisk cut its Indian Ozempic and Wegovy prices twice, most recently on March 31, 2026 [9]

Canada became the first G7 country to approve a generic semaglutide, sourced from Dr. Reddy’s in India [12]. Novo told investors in August 2026 that Canadian loss of exclusivity had “led to lower realised prices while volumes have remained broadly stable for Novo Nordisk” [13], which is a polite way of saying the brand cut price to hold share.

IQVIA also tracks the supply side: as of early 2026 there were about 74 Chinese developers and contract manufacturers working on generic semaglutide, many using synthetic routes, alongside growing activity in India [10].

None of this is legal to import for personal use into the US in most circumstances, and this article is not suggesting anyone do so. It is evidence about what prices look like when patents end.

The tariff complication

There is a new variable that did not exist in earlier patent cliffs.

In April 2026 the US imposed Section 232 tariffs of up to 100% on imported patented pharmaceuticals and their ingredients, while explicitly excluding generics and biosimilars [14]. Then, on July 21, 2026, the President announced a phased schedule that would end that exclusion [15]:

• 0% tariff on imported generics for two years, starting August 1, 2026
• 100% tariff from August 1, 2028, for one year
• 200% tariff from August 2029 onward

The stated goal is to move generic manufacturing into the United States, with the tariff described as “a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time” [15].

Most US generic medicines are imported today, with India the largest single source [16]. If that schedule is still in place when semaglutide goes generic in the early 2030s, a US generic will either be made domestically or carry a tariff. Either way, the “90% cheaper overnight” pattern familiar from past patent cliffs is not guaranteed here.

What is likely to happen to prices before 2031

Here is the counterintuitive part: US GLP-1 prices are already falling hard, years before any patent expires.

By 2026, cash prices for branded products had dropped to roughly USD 149 to USD 499 a month depending on drug and dose, against list prices above USD 1,000 [13][17]. Novo announced it would cut US list prices for Wegovy, Ozempic and Rybelsus to USD 675 a month effective January 1, 2027, roughly a 50% cut for Wegovy and 35% for Ozempic [18]. Medicare’s negotiated maximum fair price for semaglutide takes effect the same day at USD 274 for a 30-day supply, a 71% cut from the USD 959 figure used for comparison [19].

That matters for the patent cliff in a specific way. When generics arrive, they will be competing against a brand that has already cut price by two-thirds or more, in a market where the manufacturer owns its own direct-to-consumer pharmacy. The size of the drop at expiry will therefore be smaller than the drops the US saw when older blockbusters went generic from full list price.

What to watch between now and 2031

If you are tracking this, these are the events that would actually move the date:

1. Orange Book patent listings and delistings. Which device and formulation patents Novo lists determines what generic filers must challenge.
2. New ANDA filings and Paragraph IV notices. Each new filer that certifies against Novo’s patents starts a litigation clock.
3. Appeals in the Novo v. Mylan line of cases. The July 2025 ruling on induced infringement was at the district court level.
4. Whether the generic tariff schedule survives. A 200% tariff on imported generics changes the economics of who bothers to enter.
5. Where the competition actually comes from. By 2031 the US may have retatrutide, CagriSema, several amylin combinations and multiple oral agents. Generic semaglutide may arrive into a market where it is no longer the best available option, which is a very different commercial situation than a generic entering as the standard of care.

IQVIA’s own framing of the late decade is that the obesity market becomes “highly complex and deeply segmented,” with competition shifting away from raw weight loss toward tolerability, muscle preservation and outcomes beyond weight [10]. Generic semaglutide will land in the middle of that, most plausibly as an affordable entry or maintenance option rather than the premium choice.

---

Sources

1. I-MAK, “The Heavy Price of GLP-1 Drugs.” https://www.i-mak.org/glp-1
2. DrugPatentWatch, “How to bypass the GLP-1 patent lock,” 2026. https://www.drugpatentwatch.com/blog/how-to-bypass-the-glp-1-patent-lock
3. GreyB Pharsight, “Wegovy patent expiration.” https://pharsight.greyb.com/drug/wegovy-patent-expiration
4. Robins Kaplan LLP, “Novo Nordisk, Inc. v. Mylan Pharms. Inc.,” GENERICally Speaking, Q3 2025. https://www.robinskaplan.com/newsroom/insights/generically-speaking-hatch-waxman-bulletin-2025-q3-novo-nordisk-inc-v-mylan-pharms-inc
5. FindLaw, “Novo Nordisk Inc v. Mylan Pharmaceuticals Inc (2025),” D. Del. https://caselaw.findlaw.com/court/us-dis-crt-d-del/117533925.html
6. Proskauer Rose LLP, “Novo Nordisk v. Mylan: Method of Treatment Claims Must Be Aligned with Label.” https://www.proskauer.com/blog/novo-nordisk-v-mylan-method-of-treatment-claims-must-be-aligned-with-label
7. TrimRx, “When Will Tirzepatide Go Generic? Patent Timeline & Biosimilar Outlook.” https://trimrx.com/blog/tirzepatide-generic-timeline
8. GreyB, “Mounjaro patent expiration: Drug patents expiring in 2036.” https://greyb.com/blog/mounjaro-patent-expiration
9. GenericHope, “Semaglutide Price in India (2026): Generic Brands, Manufacturers & Cost Comparison.” https://generichope.com/semaglutide-price-india-generic-brands-comparison
10. IQVIA, “The outlook for obesity from 2026 to 2030,” April 21, 2026. https://www.iqvia.com/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030
11. Dr Rajat Goel, “Cost of Generic Semaglutide Injection in India 2026.” https://www.drrajatgoel.com/cost-of-generic-semaglutide-injection-in-india
12. Manville News, “Canada Approves First Generic Semaglutide,” 2026. https://manvillenews.com/article/canada-approves-first-generic-semaglutide-how-much-will-it-cost-compared-to-ozempic
13. Novo Nordisk, “Financial report for the period 1 January 2026 to 30 June 2026,” August 4, 2026. https://attachment.news.eu.nasdaq.com/a0078e15b379bff5e3b0ffdbddb3d5075
14. The White House, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” April 2, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states
15. Reuters, “Trump says generic drugs to face no US tariffs for 2 years, then 100% and 200% tariffs later,” July 21, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/trump-says-generic-drugs-face-no-us-tariffs-2-years-before-rates-100-200-later-2026-07-21
16. BioPharma Dive, “Trump threatens tariffs on imported generic drugs,” July 22, 2026. https://www.biopharmadive.com/news/trump-tariffs-generic-drugs-pharmaceuticals-impact/825879
17. CNBC, “Direct GLP-1 prescriptions are Walmart, Costco, Amazon weight-loss win,” August 1, 2026. https://www.cnbc.com/2026/08/01/glp-1-prescriptions-weight-loss-walmart-costco-amazon.html
18. Medscape / Reuters, “Novo Nordisk to Halve US List Price Of Wegovy From 2027,” February 24, 2026. https://www.medscape.com/s/viewarticle/novo-nordisk-slash-us-list-prices-ozempic-and-wegovy-wsj-2026a10005sl
19. CMS, “Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027.” https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf